Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -197.95
- Piotroski Score 3.00
- Grade Neutral
- Symbol (AWH)
- Company Aspira Women's Health Inc.
- Price $0.82
- Changes Percentage (-2.25%)
- Change -$0.02
- Day Low $0.77
- Day High $0.87
- Year High $6.01
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
- Last Earnings 12/06/2016
- Ex-Dividend for 5/16 Dividend 12/16/2016
- Dividend Payable 12/29/2016
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $3.30
- High Stock Price Target $3.30
- Low Stock Price Target $3.30
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.41
- Trailing P/E Ratio -1.49
- Forward P/E Ratio -1.49
- P/E Growth -1.49
- Net Income $-16,690,000
Income Statement
Quarterly
Annual
Latest News of AWH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Do Kawhi Leonard, Clippers have new window? Plus, TV networks want Charles Barkley
The LA Clippers face challenges with their roster changes and Kawhi Leonard's injury status. The team aims to compete in the tough Western Conference despite uncertainties, while NBA expansion talks c...
By The New York Times | 3 weeks ago -
Clippers Head Coach Ty Lue Provides Major Update on Kawhi Leonard Injury
The Los Angeles Clippers are set for a fresh start in the 2024-25 season at their new Intuit Dome arena. Superstar Kawhi Leonard's health is crucial as the team aims to boost fan interest and make an ...
By Newsweek | 1 month ago -
Clippers say they wanted Kawhi Leonard on US basketball team for Paris Olympics
USA Basketball removed Kawhi Leonard from the roster due to his knee problem, replacing him with Derrick White. Despite Leonard's desire to play, USA Basketball and the Clippers decided it was best fo...
By Fox News | 2 months ago